Champions Oncology Statistics
Want to see CSBR full AI Analyst Report?
Champions Oncology (CSBR) Stock Statistics & Valuation Metrics
Total Valuation
Champions Oncology has a market cap or net worth of $66.11M. The enterprise value is $81.67M.
- Market Cap
- $66.11M
- Enterprise Value
- $81.67M
Share Statistics
Champions Oncology has 13,918,569 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 13,918,569
- Owned by Insiders
- 15.25%
- Owned by Institutions
- 5.42%
Financial Efficiency
Champions Oncology’s return on equity (ROE) is -0.30 and return on invested capital (ROIC) is -13.28%.
- Return on Equity (ROE)
- -0.30
- Return on Assets (ROA)
- -0.04
- Return on Invested Capital (ROIC)
- -13.28%
- Return on Capital Employed (ROCE)
- -0.16
- Revenue Per Employee
- 277.69K
- Profits Per Employee
- -5,490.654
- Employee Count
- 214
- Asset Turnover
- 2.20
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Champions Oncology is -60.51. Champions Oncology’s PEG ratio is 0.29.
- PE Ratio
- -60.51
- PS Ratio
- 1.10
- PB Ratio
- 17.06
- Price to FCF
- -10.84
- Price to Operating Cash Flow
- -11.94
- PEG Ratio
- 0.29
Income Statement
In the last 12 months, Champions Oncology had revenue of 59.42M and earned -1.18M in profits. Earnings per share was -0.08.
- Revenue
- 59.42M
- Gross Profit
- 28.52M
- Operating Income
- -1.14M
- Pretax Income
- -929.00K
- Net Income
- -1.18M
- EBITDA
- 448.00K
- Earnings Per Share (EPS)
- -0.08
Cash Flow
In the last 12 months, operating cash flow was -5.56M and capital expenditures -573,000, giving a free cash flow of -6.14M billion.
- Operating Cash Flow
- -5.56M
- Free Cash Flow
- -6.14M
- Free Cash Flow per Share
- -0.44
Dividends & Yields
Champions Oncology pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -9.24%
- Earnings Yield
- -1.71%
Stock Price Statistics
- Beta
- 0.16
- 52-Week Price Change
- -31.71%
- 50-Day Moving Average
- 4.94
- 200-Day Moving Average
- 5.66
- Relative Strength Index (RSI)
- 46.15
- Average Volume (3m)
- 10.42K
Important Dates
Champions Oncology upcoming earnings date is Dec 15, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Sep 10, 2026
- Next Earnings Date
- Dec 15, 2026
- Ex-Dividend Date
- ―
Financial Position
Champions Oncology as a current ratio of 0.96, with Debt / Equity ratio of 114.55%
- Current Ratio
- 0.96
- Quick Ratio
- 0.96
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -0.80
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Champions Oncology has paid 246.00K in taxes.
- Income Tax
- 246.00K
- Effective Tax Rate
- -0.26
Enterprise Valuation
Champions Oncology EV to EBITDA ratio is 163.32, with an EV/FCF ratio of -11.90.
- EV to Sales
- 1.20
- EV to EBITDA
- 163.32
- EV to Free Cash Flow
- -11.90
- EV to Operating Cash Flow
- -13.12
Balance Sheet
Champions Oncology has $4.36M in cash and marketable securities with $10.97M in debt, giving a net cash position of -$6.61M billion.
- Cash & Marketable Securities
- $4.36M
- Total Debt
- $10.97M
- Net Cash
- -$6.61M
- Net Cash Per Share
- -$0.48
- Tangible Book Value Per Share
- $0.30
Margins
Gross margin is 49.30%, with operating margin of -1.72%, and net profit margin of -1.87%.
- Gross Margin
- 49.30%
- Operating Margin
- -1.72%
- Pretax Margin
- -1.47%
- Net Profit Margin
- -1.87%
- EBITDA Margin
- 0.74%
- EBIT Margin
- -1.46%
Analyst Forecast
The average price target for Champions Oncology is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 6.65%
- EPS Growth Forecast
- -136.61%
Scores
- Smart Score
- 2
- AI Score
- 48
